A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

NCT01561911 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Neoplasms
Lymphoma
Non-Hodgkin
B-Cell

Interventions

DRUG: Chi Lob 7/4 (A chimeric monoclonal antibody)

Sponsor

Cancer Research UK